Skip to main content
Premium Trial:

Request an Annual Quote

Genzyme, NORD Create Fund for Patients Applying to NIH Undiagnosed Diseases Program

NEW YORK (GenomeWeb News) – Genzyme and the National Organization for Rare Disorders (NORD) this week announced the creation of a fund to help patients with mysterious, undiagnosed illnesses.

The fund will be used to help applicants to the National Institutes of Health Undiagnosed Diseases Program, but who are unable to pay for the medical tests required to make them eligible for participation in the program.

The new fund is made possible in part by Genzyme employees who run the Boston Marathon to raise funds for NORD services on behalf of patients and families affected by rare diseases.

"This initiative highlights the unmet need that still exists in helping patients with rare diseases find an accurate diagnosis," Genzyme President and CEO David Meeker said in a statement. Genzyme is part of pharmaceutical firm Sanofi.

In 2014 NIH's Undiagnosed Diseases Program is expanding to include a network of major academic medical centers in the US. The fund announced today will provide funding for patients applying to all clinical sites, Genzyme and NORD said.

The UDP was created in 2008 and is managed by the National Human Genome Research Institute, the NIH Office of Rare Diseases Research, and the NIH Clinical Center. It brings together multidisciplinary teams of scientists and clinicians to try to discover the cause of diseases in select patients with disorders that are difficult to diagnose.

Patients applying for admission to the program provide their medical history and medical test results, which are evaluated by NIH physicians. NIH admits only those patients that physicians believe they can help. Only those with a baseline of preliminary medical tests are considered for participation into the program.

Filed under

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.